Q-omics provides the consensus-scored ZNF501 profile across patient tissues and cancer cell-line models. ZNF501 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF501 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF501 RNA expression shows 19,757 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ZNF501 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF501 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF501 survival associations across molecular data types. ZNF501 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF501 RNA expression–survival associations across cancer types. High ZNF501 expression shows favorable associations in KIRC, LUAD, HNSC, UCEC, UCS and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF501 RNA expression.
This table summarizes ZNF501 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF501. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF501 shows lower tumor expression in KIRC, UCEC, BRCA, KICH and THCA and higher tumor expression in LIHC. The KIRC box plot shows higher ZNF501 RNA expression in normal versus tumor tissue (log2 FC = −0.573, t-test p < 0.001).
This table shows molecular features associated with ZNF501 in patient tissues and cancer cell lines. In patient samples, ZNF501 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF501 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_SCLC.
